Analyst ratings are not perfect, but they're one of the better ways for investors to forecast future stock price movement. Here are five stocks that analysts believe have massive upside for patient, l

Where Will Pfizer Be in 5 Years?

09:15am, Friday, 29'th Sep 2023
Its business is slowing because COVID-19 revenue has fallen drastically this year. The company is also facing the loss of patent protection on multiple drugs.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings pote
In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.
Blue-chip stocks are shares of well-established, stable firms that pay dividends in most cases. It's that combination of stability and dividend income that makes them so attractive.
The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year. But seasoned investors know the ups and downs are part of the natural ebb and fl
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ginkgo Bioworks (NYSE: DNA ) stock jumped almost 14% overnight after it signed a collaboration agreement with Pfizer (NYSE: PFE ). The deal gives Ginkgo upfront cash and could eventually be worth $33
Pfizer Inc. (NYSE:PFE ) Cantor Fitzgerald Annual Global Health Conference Call September 26, 2023 3:30 PM ET Company Participants Albert Bourla - Chairman & CEO Conference Call Participants Louise Che
Pfizer Inc's chief executive said on Tuesday that almost 250,000 courses of the drugmaker's oral antiviral COVID-19 treatment Paxlovid were being administered per week as cases surged in the United St
BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acoramidis poses a threat to Pfizer's tafamidis in ATT
Pfizer Inc. said late Monday that it has restarted production at a North Carolina facility badly damaged by a tornado in July, but warned that some medications will not be in “full supply” until n
Pfizer expects operations to fully resume by the end of the year, but it warned that supply of some medicines would be affected until at least mid-2024.
Pfizer said on Monday it has restarted majority of the production lines at its tornado-hit North Carolina plant, but warned that supply of some drugs from the facility may not be fully restored until
Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE